Murphy J J, Heptinstall S, Mitchell J R
Department of Medicine, University Hospital, Nottingham.
Lancet. 1988 Jul 23;2(8604):189-92. doi: 10.1016/s0140-6736(88)92289-1.
The use of feverfew (Tanacetum parthenium) for migraine prophylaxis was assessed in a randomised, double-blind, placebo-controlled crossover study. After a one-month single-blind placebo run-in, 72 volunteers were randomly allocated to receive either one capsule of dried feverfew leaves a day or matching placebo for four months and then transferred to the other treatment limb for a further four months. Frequency and severity of attacks were determined from diary cards which were issued every two months; efficacy of each treatment was also assessed by visual analogue scores. 60 patients completed the study and full information was available in 59. Treatment with feverfew was associated with a reduction in the mean number and severity of attacks in each two-month period, and in the degree of vomiting; duration of individual attacks was unaltered. Visual analogue scores also indicated a significant improvement with feverfew. There were no serious side-effects.
在一项随机、双盲、安慰剂对照的交叉研究中，对小白菊（菊蒿）预防偏头痛的效果进行了评估。在为期一个月的单盲安慰剂导入期后，72名志愿者被随机分配，一组每天服用一粒小白菊干叶胶囊，另一组服用匹配的安慰剂，为期四个月，之后两组互换治疗，再持续四个月。通过每两个月发放一次的日记卡来确定发作的频率和严重程度；每种治疗方法的疗效也通过视觉模拟评分进行评估。60名患者完成了研究，59名患者有完整信息。服用小白菊治疗与每两个月发作的平均次数和严重程度的降低以及呕吐程度的减轻相关；单次发作的持续时间未改变。视觉模拟评分也表明小白菊治疗有显著改善。没有严重的副作用。
